



---

## INCORPORATION OF NEW SUBSIDIARIES

---

The Board of Directors (the “**Board**” or “**Directors**”) of TalkMed Group Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) wishes to announce that the Company has incorporated a wholly-owned subsidiary, TalkMed China Pte. Ltd. (“**TalkMed China**”) in Singapore on 18 September 2017.

The Company intends to utilise TalkMed China as a vehicle to explore healthcare-related collaborations in The People’s Republic of China. Further details of TalkMed China are as follows:-

|  |   |                                       |
|--|---|---------------------------------------|
| Name of subsidiary company                                   | : | TalkMed China Pte. Ltd.               |
| Issued and paid-up capital                                   | : | S\$100 comprising 100 ordinary shares |
| Percentage of issued and paid-up capital held by the Company | : | 100%                                  |

Subsequent to the incorporation of TalkMed China, TalkMed China has incorporated a 75% owned subsidiary company, TalkMed Chongqing Pte. Ltd. (“**TalkMed Chongqing**”) in Singapore on 18 September 2017, a joint venture company with minority partner ZXJ2 Holdings Pte. Ltd. (“**ZXJ2**”) with the aim of providing healthcare management services in Chongqing, The People’s Republic of China. Further details of TalkMed Chongqing are as follows:-

|  |   |   |
|--|---|---|
| Name of subsidiary company                                     | : | TalkMed Chongqing Pte. Ltd.                                   |
| Issued and paid-up capital                                     | : | S\$100 comprising 100 ordinary shares                         |
| Percentage of issued and paid-up capital held by TalkMed China | : | 75%   |
| Effective interest of the Company in TalkMed Chongqing         | : | 75% by virtue of the Company’s 100% interest in TalkMed China |

The incorporation of TalkMed China and TalkMed Chongqing is funded using internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2017.

None of the Directors, substantial shareholders or controlling shareholders of the Company has any interest, direct or indirect, in the incorporation of TalkMed China and TalkMed Chongqing, other than through their respective shareholdings in the Company.

By Order of the Board

Ang Peng Tiam  
Chief Executive Officer  
18 September 2017

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Hong Leong Finance Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, at 16 Raffles Quay #40-01A Hong Leong Building, Singapore 048581, Telephone number: (65) 6415 9886*

